<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00510822</url>
  </required_header>
  <id_info>
    <org_study_id>AFX-01</org_study_id>
    <secondary_id>EudraCT-No. 2007-001335-54</secondary_id>
    <nct_id>NCT00510822</nct_id>
  </id_info>
  <brief_title>Cimicoxib for the Treatment of Major Depression (SECIM)</brief_title>
  <official_title>Safety and Efficacy of Cimicoxib, a Selective COX-2 Inhibitor, in Combination With Sertraline Compared to Sertraline Combined With Placebo in Treatment of Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affectis Pharmaceuticals AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FGK Clinical Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Affectis Pharmaceuticals AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter study aims to investigate the safety and efficacy of cimicoxib, a selective
      COX-2 inhibitor, in combination with sertraline compared to sertraline combined with placebo
      in patients with major depression. This clinical study is based on the assumption that
      adjunctive treatment of major depression with a COX-2 inhibitor may be beneficial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients of both gender, aged between 18 and 60 years diagnosed with major depression
      by a psychiatrist and a HamD-17 score ≥ 22 will be enrolled. All patients will undergo a wash
      out period of 3 days (without e.g. medication or antidepressant medication) prior to
      receiving sertraline combined with cimicoxib or placebo. In the exceptional case where in
      opinion of the investigator concomitant psychotic treatment is needed, up to 3 mg lorazepam
      daily can additionally be administrated during this period and the first two weeks of
      treatment.Assessment of HamD-17 will be performed by trained psychiatric raters before wash
      out and at week 0 (baseline) prior to the treatment. If the HamD-17 score decreases to less
      than 22 at the second rating patients will be excluded from study.Patient must be in-patients
      during the wash out period and the first two weeks of treatment. Upon recommendation of the
      investigator, participants can become out-patients with ambulatory care at day clinics after
      the first two weeks of treatment.At baseline (week 0) patients will be randomised to one of
      the following treatment arms:· 50 mg of sertraline (one tablet/unblinded) daily plus
      cimicoxib (one tablet-50mg) twice daily.· 50 mg of sertraline (one tablet/unblinded) daily
      plus placebo (one tablet) twice daily If at study visit 3 (i.e. after 3 weeks of treatment)
      the baseline therapy dose of 50 mg of sertraline daily is considered as not therapeutically
      sufficient (increase of HamD-17 by more than 20% compared to baseline), it can be increased
      to 100 mg daily at the discretion of the investigator. The decision by the investigator to
      increase sertraline dose to 100 mg daily is allowed only at study visit 3 and is not
      permitted at any other time during the study.During the double-blind period, study visits
      will take place every week until week 6 and clinical psychiatric and safety assessments will
      be performed. Four weeks after the end of treatment the investigators or their designees will
      call the patients to capture information on how the patients feel and to assess if the
      patients experienced any SAE/AEs (e.g. hospitalisations).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Mean change on the total score of the Hamilton Depression Rating Scale (HamD-17) from baseline to endpoint (Week 6).</measure>
    <time_frame>6 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Changes from baseline to interim weekly visits (week 1 to 5) in HamD-17 score • Clinical Global Impression (CGI) score • Montgomery Asberg Depression Rating Scale (MADRS) score • Response rate, remission rate and drop out rate. • Onset of</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Sertraline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cimicoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sertraline + Cimicoxib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cimicoxib</intervention_name>
    <description>50 mg per tablet, bid (total daily dose 100 mg)</description>
    <arm_group_label>Cimicoxib</arm_group_label>
    <other_name>AFX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PLC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major depression diagnosed by psychiatrist

          -  DSM IV TR: 296.2x single depressive episode or 296.3x recurrent depressive episode

          -  HamD-17 score ≥ 22

        Exclusion Criteria:

          -  Psychotic depression, bipolar disorder, obsessive compulsive disorder, anxiety
             disorder, personality disorder, drug or alcohol abuse, schizoaffective disorders,
             schizophrenia

          -  All DSM IV TR Axis-I disorders except depression

          -  All DSM IV TR Axis-II disorders without exception

          -  Unsuccessful treatment with more than 2 antidepressant medications

          -  Concomitant use of psychotropic drugs, including mood stabilizers

          -  Immediate risk of suicidal behaviour

          -  Women who are pregnant, breast feeding or planning to become pregnant during the
             course of study, Women who are not post-menopausal, surgically sterilized or using an
             effective method of contraception

          -  Any history of cardiovascular disease (e.g. angina, heart attack, stroke, congestive
             heart failure), uncontrolled high blood pressure, documented peripheral arterial
             insufficiency and symptomatic, clinically significant claudication, or a history of
             peripheral arterial embolism

          -  History of coronary heart disease (CHD) or any other heart disease

          -  History of upper or lower gastrointestinal (GI) ulceration, perforation and/or
             obstruction

          -  History of upper or lower GI bleeding within the previous year

          -  History of inflammatory bowel disease

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manfred Rüdiger</last_name>
    <role>Study Director</role>
    <affiliation>Affectis Pharmaceuticals AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus Klagenfurt, Abteilung für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Klagenfurt</city>
        <zip>A-9020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft mbH</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>639 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ceske Budejovice</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 87</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pardubice Regional Hospital</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Medical Faculty Prague</name>
      <address>
        <city>Prague</city>
        <zip>120 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prague Psychiatric Centrum</name>
      <address>
        <city>Praha</city>
        <zip>181 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masaryk Hospital</name>
      <address>
        <city>Ústí nad Labem</city>
        <zip>401 13</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Center for Psychiatry and Psychotherapy</name>
      <address>
        <city>Berlin</city>
        <zip>D-10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LWL-Universitätsklinik Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Bonn, Center for Psychiatry and Psychotherapy</name>
      <address>
        <city>Bonn</city>
        <zip>D-53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carl Gustav Carus University Dresden, Center for Psychiatry and Psychotherapy</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georg-August-University Goettingen, Department of Psychiatry and Psychotherapy</name>
      <address>
        <city>Goettingen</city>
        <zip>D-37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Guenzburg, Center for Psychosomatic Medicine</name>
      <address>
        <city>Guenzburg</city>
        <zip>D-89312</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Jena, Center for Psychiatry and Psychotherapy</name>
      <address>
        <city>Jena</city>
        <zip>D-07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie und Psychotherapie der Universität zu Köln</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachklinik Katzenelnbogen</name>
      <address>
        <city>Limburg an der Lahn (Katzenelnbogen)</city>
        <zip>56368</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke University Magdeburg, Department of Psychiatry, Psychotherapy and Psychosomatic Medicine</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralinstitut für Seelische Gesundheit, Klinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Mannheim</city>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Psychiatry and Psychotherapy, University of Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians University Munich</name>
      <address>
        <city>Munich</city>
        <zip>D-80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Max Planck Institute of Psychiatry</name>
      <address>
        <city>Munich</city>
        <zip>D-80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bezirksklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ernst Moritz Arndt University of Greifswald, Center for Psychiatry and Psychotherapy</name>
      <address>
        <city>Stralsund</city>
        <zip>D-18437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2007</study_first_submitted>
  <study_first_submitted_qc>August 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2007</study_first_posted>
  <last_update_submitted>November 12, 2013</last_update_submitted>
  <last_update_submitted_qc>November 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cimicoxib</keyword>
  <keyword>Cox-2 inhibitor</keyword>
  <keyword>Sertraline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

